|
Name |
Asperergoster A
|
Molecular Formula | C28H40O4 | |
IUPAC Name* |
(9R,10R,12R,13R,15S,17R)-12,15-dihydroxy-17-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-1,2,9,11,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
|
|
SMILES |
C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1C[C@@H](C2=C3C=CC4=CC(=O)CC[C@@]4([C@H]3C[C@H]([C@]12C)O)C)O
|
|
InChI |
InChI=1S/C28H40O4/c1-16(7-8-17(2)26(3,4)32)21-14-23(30)25-20-10-9-18-13-19(29)11-12-27(18,5)22(20)15-24(31)28(21,25)6/h7-10,13,16-17,21-24,30-32H,11-12,14-15H2,1-6H3/b8-7+/t16-,17+,21-,22+,23+,24-,27+,28+/m1/s1
|
|
InChIKey |
RDZXYBLXIRJYJG-LSJGDYQFSA-N
|
|
Synonyms |
Asperergoster A
|
|
CAS | NA | |
PubChem CID | 156582410 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 440.6 | ALogp: | 2.8 |
HBD: | 3 | HBA: | 4 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 77.8 | Aromatic Rings: | 4 |
Heavy Atoms: | 32 | QED Weighted: | 0.537 |
Caco-2 Permeability: | -4.927 | MDCK Permeability: | 0.00002000 |
Pgp-inhibitor: | 0.999 | Pgp-substrate: | 0.959 |
Human Intestinal Absorption (HIA): | 0.617 | 20% Bioavailability (F20%): | 0.942 |
30% Bioavailability (F30%): | 0.845 |
Blood-Brain-Barrier Penetration (BBB): | 0.275 | Plasma Protein Binding (PPB): | 87.69% |
Volume Distribution (VD): | 1.204 | Fu: | 2.35% |
CYP1A2-inhibitor: | 0.018 | CYP1A2-substrate: | 0.107 |
CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.813 |
CYP2C9-inhibitor: | 0.101 | CYP2C9-substrate: | 0.153 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.118 |
CYP3A4-inhibitor: | 0.55 | CYP3A4-substrate: | 0.736 |
Clearance (CL): | 1.706 | Half-life (T1/2): | 0.752 |
hERG Blockers: | 0.533 | Human Hepatotoxicity (H-HT): | 0.419 |
Drug-inuced Liver Injury (DILI): | 0.158 | AMES Toxicity: | 0.026 |
Rat Oral Acute Toxicity: | 0.961 | Maximum Recommended Daily Dose: | 0.998 |
Skin Sensitization: | 0.911 | Carcinogencity: | 0.044 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.014 |
Respiratory Toxicity: | 0.965 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004999 | 0.842 | D0N1TP | 0.388 | ||||
ENC004997 | 0.794 | D0G5CF | 0.302 | ||||
ENC003739 | 0.631 | D0F1UL | 0.293 | ||||
ENC004998 | 0.541 | D05BTM | 0.273 | ||||
ENC003880 | 0.514 | D0T2PL | 0.273 | ||||
ENC004737 | 0.495 | D01QUS | 0.271 | ||||
ENC004022 | 0.495 | D0G8OC | 0.267 | ||||
ENC001861 | 0.495 | D04SFH | 0.262 | ||||
ENC003368 | 0.482 | D06XMU | 0.261 | ||||
ENC004834 | 0.474 | D06JPB | 0.258 |